Literature DB >> 16938528

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Mi-Jung Kim1, Jae Y Ro, Sei-Hyun Ahn, Hak Hee Kim, Sung-Bae Kim, Gyungyub Gong.   

Abstract

DNA microarray profiling studies have led to the classification of invasive breast carcinoma into luminal/estrogen receptor-positive, normal breast-like, Her2/neu-overexpressing, and basal-like types. Among these groups, the basal-like subtype is associated with the poorest clinical outcome in Western countries. To date, the clinicopathologic characteristics of the basal-like carcinomas, compared with other subtypes, have not been described in the Korean population. In this study, we used tissue microarray to examine the expression of basal cytokeratins (CK) (CK5 and CK14) and luminal CK (CK8/18), epidermal growth factor receptor, c-kit, hormone receptors (HRs), p53, and Her2/neu in 776 consecutive patients diagnosed with invasive breast carcinoma from January 1993 to December 1998 and categorized these cases into 5 subgroups (basal-like, HR-expressing, Her2/neu-overexpressing, HR and Her2/neu-expressing, and null subtypes negative for all markers), based on the immunohistochemical data. We identified cases of 114 (14.7%) basal-like, 345 (44.5%) HR-expressing, 133 (17.1%) Her2/neu-overexpressing, 61 (7.8%) HR and Her2/neu-expressing, and 123 (15.9%) null subtypes. Histologically, most basal-like breast cancers were invasive ductal carcinoma, not otherwise specified (98 cases, 86.0%), with high nuclear and/or histologic grades, and most metaplastic carcinomas (6 [75.0%] of 8 cases) were the basal-like subtype. Both basal-like and Her2/neu-overexpressing subtypes were associated with larger tumor sizes (mean, 3.6 and 3.3 cm, respectively) than the HR-expressing group (mean, 2.8 cm) (P = .001 and P = .036, respectively). Nodal stage of Her2/neu-overexpressing subtype was higher than that of basal-like subtype; however, overall stage was not different between the 2 groups (P = .010 and .123, respectively). Distant metastasis was most frequently observed in the Her2/neu-overexpressing subtype (33.8%), which was prognostically the worst subgroup of breast cancers. In contrast to previous findings from Western countries, our analyses reveal that the Her2/neu status is the most important prognostic factor of breast cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938528     DOI: 10.1016/j.humpath.2006.04.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  112 in total

1.  Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer.

Authors:  Minqing Wu; Weidong Wei; Xiangsheng Xiao; Jiaoli Guo; Xinhua Xie; Laisheng Li; Yanan Kong; Ning Lv; Weihua Jia; Yin Zhang; Xiaoming Xie
Journal:  Med Oncol       Date:  2012-06-04       Impact factor: 3.064

2.  Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.

Authors:  Kanwal P S Raghav; Leonel F Hernandez-Aya; Xiudong Lei; Marianan Chavez-Macgregor; Funda Meric-Bernstam; Thomas A Buchholz; Aysegul Sahin; Kim-Anh Do; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-08-11       Impact factor: 6.860

3.  Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.

Authors:  Amanda I Phipps; Diana S M Buist; Kathleen E Malone; William E Barlow; Peggy L Porter; Karla Kerlikowske; Christopher I Li
Journal:  Cancer Causes Control       Date:  2010-12-24       Impact factor: 2.506

4.  Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified.

Authors:  Shuling Wang; Weidong Li; Ning Liu; Tongxian Zhang; Han Liu; Junjun Liu; Fen Liu; Wei Zhang; Estifanos P Gebreamlak; Yun Niu
Journal:  Med Oncol       Date:  2012-02-07       Impact factor: 3.064

5.  Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast.

Authors:  Hyung Seok Park; Seho Park; Joo Hee Kim; Ju-Hyun Lee; So-Young Choi; Byeong-Woo Park; Kyong-Sik Lee
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

6.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

7.  Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Authors:  Christopher I Li; Justin E Mirus; Yuzheng Zhang; Arturo B Ramirez; Jon J Ladd; Ross L Prentice; Martin W McIntosh; Samir M Hanash; Paul D Lampe
Journal:  Breast Cancer Res Treat       Date:  2012-08-19       Impact factor: 4.872

8.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

10.  Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.

Authors:  Christopher I Li; Elisabeth F Beaber; Mei-Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.